Advances in the pathogenesis and treatment of IBD

Clin Immunol. 2009 Jul;132(1):1-9. doi: 10.1016/j.clim.2009.02.006. Epub 2009 Mar 24.

Abstract

Crohn's disease and ulcerative colitis are chronic remitting and relapsing inflammatory bowel diseases. We present a typical case of Crohn's disease in a young woman and discuss potential treatment options. Crohn's disease and ulcerative colitis likely result from interaction of multiple genetic and environmental risk and protective factors. Both are diseases ultimately caused by immune dysregulation. Medical therapy is with mesalamine compounds, corticosteroids, immunomodulators and/or biologics that target TNFalpha signaling or alpha4-integrin-mediated trafficking. Investigational agents include those targeted against other cytokines and costimulatory molecules or designed to promote immune regulation such as exposure to helminths which is a focus of this review.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Adult
  • Animals
  • Female
  • Genetic Predisposition to Disease / genetics
  • Humans
  • Immunity, Mucosal / immunology
  • Immunosuppressive Agents / therapeutic use
  • Inflammatory Bowel Diseases / genetics
  • Inflammatory Bowel Diseases / immunology*
  • Inflammatory Bowel Diseases / therapy*
  • Methotrexate / therapeutic use
  • Nematoda / immunology

Substances

  • Immunosuppressive Agents
  • Methotrexate